article thumbnail

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

One of the biggest pharmaceutical companies is placing a big bet that nasal glucagon is going to get FDA approval in the near future. has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. Eli Lilly and Co.

article thumbnail

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

One of the biggest pharmaceutical companies is placing a big bet that nasal glucagon is going to get FDA approval in the near future. has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. Eli Lilly and Co.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M

Lloyd Price

and pharmaceutical entrepreneur Robert Duggan. February 2015: Dr. Venter says he has been able to transmit DNA over the internet, but adds this isn’t quite the same as the teleportation in ‘Star Trek.’ But key facets of its business didn’t develop as planned, say people familiar with the company.

article thumbnail

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

One of the biggest pharmaceutical companies is placing a big bet that nasal glucagon is going to get FDA approval in the near future. has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. Eli Lilly and Co.

article thumbnail

Like banks, healthcare will become digital-first in 2022, Zoom healthcare lead says

Healthcare IT News - Telehealth

By 2015, 45% of adults under 29 and 25% of all adults in a nationally representative sample did not have a PCP. These allow pharmaceutical companies and contract research organizations to reach a more diverse patient pool and create a more accessible experience for patients as research no longer needs to be tied to specific trial sites.

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Lars Staal Wegner, M.D.

BioTech 88
article thumbnail

Asaya and medical cannabis care in the era of personalised medicine

Lloyd Price

Desperate for medical insights without delay, researchers, pharmaceutical companies and government agencies turned to health information captured through real-world data sources. A new medication is introduced to the market via legislation rather than through formal drug development practices (3); 3. 6 May 2017. 4 Reynolds P.